Format

Send to

Choose Destination
Int Immunopharmacol. 2018 Oct;63:58-65. doi: 10.1016/j.intimp.2018.07.023. Epub 2018 Jul 31.

Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?

Author information

1
Departments of Gastrointestinal surgery, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, PR China; The Affiliated Drum Tower Clinical College of NanJing Medical University, Nanjing, PR China.
2
XuZhou Medical University, Xuzhou, PR China.
3
Departments of Gastrointestinal surgery, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, PR China.
4
Departments of Gastrointestinal surgery, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, PR China. Electronic address: songjunwk@126.com.
5
Departments of Gastrointestinal surgery, the Affiliated Drum Tower hospital of NanJing Medical University, Nanjing, PR China. Electronic address: guan-wx@163.com.

Abstract

Adenosine (ADO), generated by the ectonucleotidase CD39 and CD73 from ATP, interacts with its specific G protein-coupled receptors, which can impair anti-tumor immune responses inhibiting the infiltration and function of CD8+ T cell and natural killer cell. Recent studies have also identified that ADO pathway plays a critical role in tumor immune surveillance, especially for some non-solid cancers. In addition, although immune checkpoint therapy targeting ADO pathway in gastric cancer is still in an early phase, encouraging results have come out from some drugs targeting ADO pathway. Therefore, target ADO signaling may be a new promising strategy to treat gastric cancer. In this review, we summarized recent works on the role of ADO in cancer immunotherapy and also discussed relative mechanisms underlying the function of ADO signaling in cancer immune responses.

KEYWORDS:

A2aR signaling; Adenosine; gastric cancer; immunotherapy

PMID:
30075429
DOI:
10.1016/j.intimp.2018.07.023
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center